End-To-End Digital Transformation Presents Banks With a Trillion-Dollar Profit Opportunity, Reveals the Newly Launched Temenos Value Benchmark Program
Temenos (SIX: TEMN), the banking software company today announced the first set of results from the Temenos Value Benchmark, a strategic, survey-based program providing in-depth analysis of how software capabilities impact a bank’s profitability. Key findings show that top-performing banks using Temenos software invest in end-to-end digitization, underpinned by state-of-the-art analytics to achieve industry-leading profitability levels.
As a result, these top performing banks using Temenos software have achieved industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average. These results show the tangible value to be gained if banks are able to digitally transform their businesses and move from legacy-systems to modern, off-the-shelf packaged software running on the latest cloud-native, cloud-agnostic, API-based technology.
Banks are challenged by tough macro-economic conditions, the rise of new competition and evolving customer demands, combined with crippling legacy architectures. However, they have an immense opportunity to harness the power of digitization to transform their business and achieve dramatic profitability improvements. The average return on equity for participating banks in the Temenos Value Benchmark at 15.6% is significantly higher than current industry-average returns on equity of 8% to 10%. This differential translates into up to a massive additional one trillion USD profit potential for the global banking industry were it to digitally transform, assuming a $140 billion increment in operating profit for every 1% increase in return on equity1.
Max Chuard, Chief Executive Officer, Temenos, said: “There is a trillion dollar profit opportunity for banks which move away from legacy systems to modern packaged software running on the latest cloud-native, cloud-agnostic, API-first technology. The case for digital transformation has never been stronger and the urgency for change has never been greater. The results of the Temenos Value Benchmark Program show that Temenos clients are amongst the top performing banks in the industry and by transforming their end-to-end digital banking platform, they have been able to achieve industry-leading profitability levels while innovating faster and delivering exceptional digital experiences for their customers. For most banks, digital transformation is a once in a life project, for us is our full time job. We are proud to take a bank live on our software every day of the week. We help institutions of all types - from large global banks such as Nordea and Standard Chartered to digital-only banks like Varo Money and Volt Bank - to unlock the business value of the digital banking opportunity and drive best-in-class performance and profitability.”
Kanika Hope, Global Strategic Business Advisory Director, Temenos, said: “As the world’s leading provider of packaged banking software, it is our vision and mission to help our clients achieve tangible business value from their IT investment. We therefore launched the Temenos Value Benchmark, a unique program to provide our banking clients, tangible, data-driven insights and recommendations into their business performance, in the spirit of a true strategic partner. Through our benchmark study, we collected thousands of data points around financial and operational metrics as well as qualitative best practices across the entire banking value chain, to understand how specific solution enablers and best practices drive high performance such as better cost-income ratios and improved returns on equity and assets.”
Five Drivers of high-performing banks:
The Temenos Value Benchmark has revealed that top performing banks who have digitally transformed their business and moved away from legacy-systems are able to differentiate across five key areas:
- Product innovation and growth: They launch products and services faster, which result in higher customer growth. These banks can focus their IT spend on growth and innovation rather than maintenance.
- Customer centricity: They engage digitally with more of their customers, cross-sell more and on-board customers faster. All of these contribute to higher customer satisfaction.
- Operational efficiency: They have higher levels of automation driven by straight through processing both, in the front and the back office allowing support of more customers with fewer staff.
- Effective risk and compliance: They have more efficient and effective compliance functions, leading to better staff productivity and more efficient operations. They also spend less of their IT budget on regulation.
- Advanced analytics: They use analytics widely and effectively with a higher proportion of self-service reports and a greater proportion of business users using analytics. They also have a stronger data foundation in terms of lower data duplication across their systems.
Dan Dickinson, CIO, Equitable (EQ) Bank Canada, said: “A great example of the value I got from the Temenos Value Benchmark and why I would encourage my banking counterparts to participate in this program, is the metric I received on the very first page of the report: IT cost as a revenue percentage. This benchmark metric paid off immediately as it revealed to me the true cost of my IT and how I must continue to optimize and automate as I grow my customer base as Canada’s first digital challenger.”
The Temenos Value Benchmark
The Temenos Value Benchmark is a strategic survey-based program to discuss the business and IT metrics and best practices enabled by a bank’s investment in technology. As part of this exercise, banks receive a customized report free of charge comparing their business performance with Temenos clients including executive-level summary of findings with business and IT insights structured along eight banking business and IT domains, across the banking value chain.
To read the insights of the first wave of results from the Temenos Value Benchmark, please visit here.
– Ends –
About Temenos
Temenos AG (SIX: TEMN), headquartered in Geneva, is the world’s leader in banking software, partnering with banks and other financial institutions to transform their businesses and stay ahead of a changing marketplace. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic front office and core banking, payments, fund management and wealth management software products enabling banks to deliver consistent, frictionless customer journeys and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve industry-leading cost-income ratios of 25.2% and returns on equity of 25.0%, 2X better than the industry average. These clients also invest over 53% of their IT budget on growth and innovation versus maintenance, which is 2.5X the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information please visit www.temenos.com.
1 McKinsey Global Banking Review 2017
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190925005319/en/
Contact information
Media Contacts
Jessica Wolfe & Grace Collins
Temenos Global Public Relations
Tel: +1 610 232 2793 & + 44 20 7423 3969
Email : press@temenos.com
Alistair Kellie & Andrew Adie
Newgate Communications on behalf of Temenos
Tel: +44 20 7680 6550
Email: allnewgatetemenos@newgatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
